Blueprint Medicines Corporation announced its financial results for the first quarter ended March 31, 2025, reporting global AYVAKIT net product revenues of $149.4 million. This represents a 61% year-over-year growth compared to the first quarter of 2024, contributing to total revenues of $149.413 million for the quarter.
The company raised its full-year 2025 global AYVAKIT net product revenue guidance to a range of $700 million to $720 million, an increase from the previous range of $680 million to $710 million. This upward revision reflects favorable commercial mix and continued strength in underlying growth fundamentals, reinforcing the path to achieving $2 billion in global AYVAKIT net product revenues by 2030.
Blueprint Medicines reported a net income of $0.496 million, or $0.01 per share, for the first quarter of 2025. The company ended the quarter with a strong cash position of $899.784 million in cash, cash equivalents, and investments. Operating cash burn is expected to continue to reduce year-over-year in 2025, and the company realized a $50.0 million equity investment gain from the sale of its IDRx stake during the quarter. Additionally, Blueprint initiated BLU-808 proof-of-concept studies in allergic rhinoconjunctivitis and chronic urticaria.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.